Novo Integrated Sciences (Novo Integrated Sciences) Debt-to-Equity : 0.24 (As of Feb. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Novo Integrated Sciences Debt-to-Equity?

Novo Integrated Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $3.64 Mil. Novo Integrated Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $1.70 Mil. Novo Integrated Sciences's Total Stockholders Equity for the quarter that ended in Feb. 2024 was $22.19 Mil. Novo Integrated Sciences's debt to equity for the quarter that ended in Feb. 2024 was 0.24.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Novo Integrated Sciences's Debt-to-Equity or its related term are showing as below:

NVOS' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.3 Med: 0.16 Max: 7.99
Current: 0.24

During the past 13 years, the highest Debt-to-Equity Ratio of Novo Integrated Sciences was 7.99. The lowest was -1.30. And the median was 0.16.

NVOS's Debt-to-Equity is ranked better than
65.22% of 552 companies
in the Healthcare Providers & Services industry
Industry Median: 0.49 vs NVOS: 0.24

Novo Integrated Sciences Debt-to-Equity Historical Data

The historical data trend for Novo Integrated Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Integrated Sciences Debt-to-Equity Chart

Novo Integrated Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Debt-to-Equity

Get a 7-Day Free Trial

0.17

0.15

0.31

0.58

0.18

Novo Integrated Sciences Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Debt-to-Equity	Get a 7-Day Free Trial															0.16	0.17	0.18	0.20	0.24

Competitive Comparison of Novo Integrated Sciences's Debt-to-Equity

For the Medical Care Facilities subindustry, Novo Integrated Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Integrated Sciences's Debt-to-Equity Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Novo Integrated Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Novo Integrated Sciences's Debt-to-Equity falls into.

Novo Integrated Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Novo Integrated Sciences's Debt to Equity Ratio for the fiscal year that ended in Aug. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.713	+	1.759)	/	24.816
	=	0.18

Novo Integrated Sciences's Debt to Equity Ratio for the quarter that ended in Feb. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.638	+	1.703)	/	22.189
	=	0.24

Novo Integrated Sciences (NAS:NVOS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Novo Integrated Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Novo Integrated Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Integrated Sciences (Novo Integrated Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Novo Integrated Sciences Inc (NAS:NVOS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

11120 NE 2nd Street, Suite 100, Bellevue, WA, USA, 98004

Website

https://www.novointegrated.com

Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services which generates majority of the revenue, and product sales.

Executives

Sarfaraz Ali	director	C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Robert Letterio Oliva	director	115 BELFIELD RD, TORONTO A6 L0J 1C0
Sterling M. Jimenez	officer: Principal Financial Officer	C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Michael Ross Pope	director	1045 PROGRESS CIRCLE, LAWRENCEVILLE, GEORGIA GA 30043
Alex Flesias	director	41 LANDMARK COURT, UNIONVILLE A6 L3R 9N7
Michael Joseph Gaynor	director	49 BALMORAL ST, KEMPTVILLE A6 K0G 1J0
Robert Mattacchione	director, 10 percent owner, officer: Chief Executive Officer	79 SELVAPIANO CRES, WOODBRIDGE A6 L4H 0X1
Pierre Joseph Dalcourt	director, 10 percent owner	35 BRYANT ST , BOX 2230, HEARST A6 P0L 1N0
Christopher Mehlin David	director, officer: President	10425 SE 22ND ST., BELLEVUE WA 98004
Thomas Edward Bray	officer: Principal Financial Officer	C/O NOVO INTEGRATED SCIENCES, INC., 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Rebecca Aw Mcdonald	officer: Chief Accounting Officer	1301 INTERNATIONAL SPEEDWAY BLVD., DELAND FL 32724
James Jr Teters	director	1200 FLIGHTLINE BLVD, STE 5, DELAN FL 32724
Phyllis Rouse	officer: secretary	1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Jay Hilden	officer: President & CEO	1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Robert Adamo	director	1200 FLIGHTLINE BOULEVARD, SUITE 5, DELAND FL 32724